Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.
作者信息
Schrauben Sarah J, Becker William C
机构信息
Department of Medicine, Renal, Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):3-4. doi: 10.2215/CJN.0000000000000031.
Abstract
摘要
相似文献
1
Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.肾移植受者疼痛药物治疗中风险与不确定获益的权衡
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):3-4. doi: 10.2215/CJN.0000000000000031.
2
Interventions for preventing thrombosis in solid organ transplant recipients.实体器官移植受者的血栓预防干预措施。
Cochrane Database Syst Rev. 2021 Mar 15;3(3):CD011557. doi: 10.1002/14651858.CD011557.pub2.
3
Antibiotics for asymptomatic bacteriuria in kidney transplant recipients.肾移植受者无症状菌尿的抗生素治疗
Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD011357. doi: 10.1002/14651858.CD011357.pub2.
4
Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation.供体BK多瘤病毒复制对活体供体移植中受体感染的影响。
Transpl Infect Dis. 2018 Aug;20(4):e12917. doi: 10.1111/tid.12917. Epub 2018 Jun 11.
5
Fracture Incidence in Adult Kidney Transplant Recipients.成年肾移植受者的骨折发生率
Transplantation. 2016 Jan;100(1):167-75. doi: 10.1097/TP.0000000000000808.
6
The Case | Knee pain and allograft dysfunction in a kidney transplant recipient.病例 | 肾移植受者的膝关节疼痛与同种异体移植物功能障碍
Kidney Int. 2020 Feb;97(2):429-430. doi: 10.1016/j.kint.2019.07.007.
7
Metabolic risk profile in kidney transplant candidates and recipients.肾移植候选者和受者的代谢风险特征。
Nephrol Dial Transplant. 2019 Mar 1;34(3):388-400. doi: 10.1093/ndt/gfy151.
8
Recipient Comorbidity and Survival Outcomes After Kidney Transplantation: A UK-wide Prospective Cohort Study.受者合并症与肾移植后生存结局：英国范围前瞻性队列研究。
Transplantation. 2020 Jun;104(6):1246-1255. doi: 10.1097/TP.0000000000002931.
9
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.一项 ASP0113（一种基于 DNA 的疫苗）用于预防 CMV 血清阴性肾移植受者接受 CMV 血清阳性供体肾后发生 CMV 感染的随机、2 期研究。
Am J Transplant. 2018 Dec;18(12):2945-2954. doi: 10.1111/ajt.14925. Epub 2018 Jun 20.
10
Bacterial and fungal bloodstream infections in pediatric liver and kidney transplant recipients.儿童肝、肾移植受者的细菌和真菌感染性血流感染。
BMC Infect Dis. 2021 Jun 8;21(1):541. doi: 10.1186/s12879-021-06224-2.
本文引用的文献
1
Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses.美国涉及非苯二氮䓬类催眠/镇静剂的过量用药死亡情况：趋势分析
Lancet Reg Health Am. 2022 Jan 24;10:100190. doi: 10.1016/j.lana.2022.100190. eCollection 2022 Jun.
2
Gabapentin, Concomitant Prescription of Opioids, and Benzodiazepines among Kidney Transplant Recipients.肾移植受者中加巴喷丁、阿片类药物和苯二氮䓬类药物的同时处方。
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):91-98. doi: 10.2215/CJN.0000000000000019.
3
Psychological Interventions for the Treatment of Chronic Pain in Adults.成人慢性疼痛的心理干预治疗。
Psychol Sci Public Interest. 2021 Sep;22(2):52-95. doi: 10.1177/15291006211008157.
4
Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.实施药师护理经理模式，以扩大阿片类药物使用障碍治疗药物的可及性。
Am J Health Syst Pharm. 2021 Feb 8;78(4):354-359. doi: 10.1093/ajhp/zxaa405.
5
Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.慢性疼痛临床试验结果的解读：IMMPACT推荐的考量因素
Pain. 2020 Nov;161(11):2446-2461. doi: 10.1097/j.pain.0000000000001952.
6
Prevalence and Profile of High-Impact Chronic Pain in the United States.美国高影响慢性疼痛的流行情况和特征。
J Pain. 2019 Feb;20(2):146-160. doi: 10.1016/j.jpain.2018.07.006. Epub 2018 Aug 7.
7
Prescription opioid use before and after kidney transplant: Implications for posttransplant outcomes.肾移植前后的处方阿片类药物使用：对移植后结局的影响。
Am J Transplant. 2018 Dec;18(12):2987-2999. doi: 10.1111/ajt.14714. Epub 2018 Apr 17.
8
Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication.多重用药与死亡率：来自一大群老年人的新见解，通过检测多重疾病的效应修正和按指征全面校正混杂因素
Eur J Clin Pharmacol. 2017 Aug;73(8):1041-1048. doi: 10.1007/s00228-017-2266-7. Epub 2017 May 24.
9
Management of Polypharmacy in Dialysis Patients.透析患者多重用药的管理
Semin Dial. 2015 Jul-Aug;28(4):427-32. doi: 10.1111/sdi.12377. Epub 2015 Apr 9.
10
Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.透析依赖患者的药物重整和治疗管理：需要系统方法。
Clin J Am Soc Nephrol. 2013 Nov;8(11):1988-99. doi: 10.2215/CJN.01420213. Epub 2013 Aug 29.
Zotero 插件